Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of DW6012 FDC vs Loose Combination in Healthy Volunteers
NCT05403281Phase 1Completed
- Sponsor
- Dongwha Pharmaceutical Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dongwha Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration up to 48 hours and Maximum Plasma Concentration up to 48 hours. Started Nov 2021; status: completed.
02
Drugs
dapagliflozin + sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05403281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403281.